Glucose 40% Labesfal

Glucose 40% Labesfal is an intravenous solution containing 40% w/v glucose as the active ingredient. It is supplied as a sterile liquid for parenteral administration and classified as an excipient/solvent used in parenteral nutrition. The product is marketed in the EU and requires prescription.

Glucose 40% Labesfal is indicated for several clinical situations where rapid carbohydrate delivery is needed.

- Management of acute hypoglycemia in patients who cannot ingest oral glucose, providing an immediate source of carbohydrate. - Fluid and electrolyte replacement as part of intravenous therapy, helping to maintain volume status while delivering energy. - Component of total parenteral nutrition formulations, contributing caloric content and preventing catabolism during periods without enteral intake. - Support during perioperative fasting or prolonged starvation, supplying glucose to sustain cellular metabolism. - Adjunct in the treatment of hyperosmolar states in diabetic emergencies, helping to lower serum osmolality while correcting glucose deficits.

Intravenous administration of Glucose 40% Labesfal may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common: - Local irritation, erythema, or pain at the infusion site, especially with rapid infusion rates. - Transient elevation of blood glucose levels (hyperglycemia) that typically resolves with monitoring and adjustment of infusion rate. - Electrolyte imbalances such as mild hypokalemia, hyponatremia, or shifts in calcium levels due to osmotic effects. - Nausea, mild abdominal discomfort, or a feeling of fullness during or shortly after infusion.

Serious: - Severe hyperglycemia that may precipitate osmotic diuresis, dehydration, or, in predisposed individuals, diabetic ketoacidosis. - Allergic reactions ranging from urticaria and pruritus to anaphylactic shock, requiring immediate medical intervention. - Volume overload leading to pulmonary edema or congestive heart failure in patients with compromised cardiac function.

When using Glucose 40% Labesfal, clinicians should observe several precautions to minimize risks and ensure safe administration.

- Verify patient’s blood glucose level before initiating infusion to avoid exacerbating hyperglycemia. - Adjust infusion rate according to individual metabolic needs and monitor glucose frequently during therapy. - Assess fluid status and cardiac function, especially in patients at risk for volume overload or heart failure. - Use compatible IV sets and avoid mixing with solutions that may precipitate or cause incompatibility. - Monitor electrolytes, particularly potassium and sodium, as rapid glucose infusion can shift serum concentrations. - Exercise caution in patients with known glucose intolerance, diabetes mellitus, or metabolic disorders.

Glucose 40% Labesfal can interact with other intravenously administered agents; awareness of these interactions helps prevent complications.

Avoid: - Co‑administration with high‑dose insulin infusions without appropriate glucose monitoring, as this may precipitate severe hypoglycemia. - Mixing with calcium-containing solutions that can cause precipitation, especially in alkaline pH environments.

Use with caution: - Concurrent use with diuretics (e.g., furosemide) may exacerbate electrolyte shifts; monitor potassium and sodium levels. - Administration alongside catecholamines (e.g., epinephrine) can increase metabolic demand and raise glucose levels; adjust infusion rates accordingly. - Use with other hyperosmolar solutions (e.g., mannitol) may increase risk of hyperosmolar syndrome; monitor serum osmolality.